eligibility_summary
Eligibility: Adults ≥18 with histologically/cytologically confirmed locally advanced or metastatic NSCLC, ECOG 0–1, life expectancy ≥3 months, and consent. Exclude: uncontrolled/symptomatic CNS metastases, unresolved >Grade 1 prior-therapy AEs (except alopecia/fatigue), inadequate organ/bone marrow function, pregnant/breastfeeding, allergy/hypersensitivity to SSGJ-707.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase II, first-line advanced NSCLC trial evaluating SSGJ-707 plus chemotherapy vs PD-1/L1 inhibitor plus chemotherapy. Interventions and mechanisms: 1) SSGJ-707: bispecific antibody immunotherapy (targets not specified) intended to engage two antitumor targets and enhance immune-mediated tumor killing. 2) PD-1/L1 inhibitor: monoclonal antibody checkpoint inhibitor blocking PD-1/PD-L1 to restore cytotoxic T-cell function. 3) Carboplatin: platinum chemotherapy causing DNA crosslinks and apoptosis. 4) Pemetrexed: antifolate chemotherapy inhibiting thymidylate synthase and other folate enzymes, blocking nucleotide synthesis. 5) Paclitaxel or nab-paclitaxel: microtubule-stabilizing chemotherapies arresting mitosis. Targets/pathways: PD-1/PD-L1 on T cells and tumor/immune cells, T-cell activation/exhaustion, tumor DNA damage response, folate-dependent nucleotide synthesis, and microtubule dynamics. Non-squamous: pemetrexed, squamous: paclitaxel/nab-paclitaxel.